Biphasic insulin aspart 30 (
BIAsp 30) has been used in patients for almost a decade; There is a wealth of knowledge from clinical trials to document its efficacy and safety and suggest that
BIAsp 30 is an option for initiation and intensification of
insulin therapy in patients with
type 2 diabetes mellitus (T2DM). The A1chieve was a non-interventional study that explored the safety and effectiveness of initiating or switching to
insulin analogues in routine clinical practice in more than 60,000 patients from 28 different countries. In this manuscript, we discuss the findings from the subgroup of the Indian cohort who were treated with
BIAsp 30. In a cohort of 15287 who were on
BIAsp 30, 12645 (83%) were
insulin naive and 2642 (17%) had been on
insulin therapy earlier. Glycaemic parameters were high at baseline. Mean (SD) HbA1c was 9.2% (1.3) in the these and was comparable in the
insulin naive and
insulin experienced groups. After 24 weeks of
therapy with
BIAsp 30, there were reductions in HbA1c in both the
insulin naive group, [-1.8 (1.3)] and
insulin experienced group [-1.6 (1.3)]. Fasting plasma
glucose (FPG) and postprandial plasma
glucose (PPG) levels were also reduced significantly from baseline [-3.4 (2.7) and -4.8 (3.8) mmol/L, respectively, p < 0.05). Overall, hypoglycaemia decreased from 1.33 events/patient years at baseline to 0.19 events/patient years at 24 weeks. There was also an increase in quality of life score as evaluated by EQ-5D questionnaire. Initiating
insulin therapy with or switching to
BIAsp 30 in patients with poor glycaemic control leads to an improvement in glycaemic profile with no major hypoglycaemia or clinically significant
weight gain.
Therapy with
BIAsp 30 also improves the quality of life in patients with
type 2 diabetes.